Get started
LAVA Therapeutics N.V.LAVA Therapeutics N.V.LAVA Therapeutics N.V.

LAVA Therapeutics N.V.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

LVTX chart


Full chart

LVTX upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪27.08 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.0307 USD
Net income (FY)
‪−41.97 M‬ USD
Revenue (FY)
‪6.77 M‬ USD
Shares float
‪14.17 M‬
Beta (1Y)
1.12

Employees


Employees (FY)
37
Change (1Y)
−32 −46.38%
Revenue / Employee (1Y)
‪182.95 K‬ USD
Net income / Employee (1Y)
‪−1.13 M‬ USD

About LAVA Therapeutics N.V.


Sector
Health Technology
Industry
Biotechnology
CEO
Stephen Allen Hurly
Website
lavatherapeutics.com
Headquarters
Utrecht
Founded
2016
ISIN
NL0015000AG6
FIGI
BBG00L04L545
LAVA Therapeutics NV is an immuno-oncology company, which engages in the proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company was founded by Erik van den Berg in 2016 and is headquartered in Utrecht, the Netherlands.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

LVTX news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of LVTX is 0.9752 USD — it has decreased by −4.49% in the past 24 hours. Watch LAVA Therapeutics N.V. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange LAVA Therapeutics N.V. stocks are traded under the ticker LVTX.
LVTX stock has fallen by −8.91% compared to the previous week, the month change is a −34.41% fall, over the last year LAVA Therapeutics N.V. has showed a −35.88% decrease.
We've gathered analysts' opinions on LAVA Therapeutics N.V. future price: according to them, LVTX price has a max estimate of 3.00 USD and a min estimate of 2.00 USD. Watch LVTX chart and read a more detailed LAVA Therapeutics N.V. stock forecast: see what analysts think of LAVA Therapeutics N.V. and suggest that you do with its stocks.
LVTX reached its all-time high on Mar 31, 2021 with the price of 17.2000 USD, and its all-time low was 0.9617 USD and was reached on Dec 18, 2024. View more price dynamics on LVTX chart.
See other stocks reaching their highest and lowest prices.
LVTX stock is 4.17% volatile and has beta coefficient of 1.12. Track LAVA Therapeutics N.V. stock price on the chart and check out the list of the most volatile stocks — is LAVA Therapeutics N.V. there?
Today LAVA Therapeutics N.V. has the market capitalization of ‪25.87 M‬, it has decreased by −14.05% over the last week.
Yes, you can track LAVA Therapeutics N.V. financials in yearly and quarterly reports right on TradingView.
LAVA Therapeutics N.V. is going to release the next earnings report on Mar 20, 2025. Keep track of upcoming events with our Earnings Calendar.
LVTX earnings for the last quarter are −0.46 USD per share, whereas the estimation was −0.33 USD resulting in a −39.39% surprise. The estimated earnings for the next quarter are −0.29 USD per share. See more details about LAVA Therapeutics N.V. earnings.
LAVA Therapeutics N.V. revenue for the last quarter amounts to 0.00 USD, despite the estimated figure of 0.00 USD. In the next quarter, revenue is expected to reach ‪2.50 M‬ USD.
LVTX net income for the last quarter is ‪−12.30 M‬ USD, while the quarter before that showed ‪−8.30 M‬ USD of net income which accounts for −48.22% change. Track more LAVA Therapeutics N.V. financial stats to get the full picture.
No, LVTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 37.00 employees. See our rating of the largest employees — is LAVA Therapeutics N.V. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. LAVA Therapeutics N.V. EBITDA is ‪−27.00 M‬ USD, and current EBITDA margin is −620.11%. See more stats in LAVA Therapeutics N.V. financial statements.
Like other stocks, LVTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade LAVA Therapeutics N.V. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So LAVA Therapeutics N.V. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating LAVA Therapeutics N.V. stock shows the strong sell signal. See more of LAVA Therapeutics N.V. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.